Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
AbbVie, ACELYRIN, Amgen, baby, billable, Biochemistry, Biology, bundled, Carolina, CARsgen, Celularity, Chapel, Charity, Dartmouth, developmental, doctoral, Dr, excise, fellowship, grace, Hamilton, Hill, joining, lump, MD, nominated, North, Panel, Pharm, Pharmacology, PharmD, point, Precigen, predominant, professional, promulgated, recognition, School, Scripture, Stemcentrx, supervision, Tmunity, Toxicology, Vice
Removed:
beneficially, Celyad, feel, Intrexon, IPO, MolMed, organizational, unsolicited
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view